Galera Therapeutics filings document a clinical-stage oncology company’s material agreements, governance matters, capital structure and operating disclosures. The company’s SEC reports include 8-K events for asset transactions involving dismutase mimetics, amendments to preferred-stock terms, conversions of Series B Non-Voting Convertible Preferred Stock, pre-funded warrant exercises, and executive compensation arrangements.
Galera’s proxy and annual-meeting materials cover stockholder voting procedures, director nominations, governance requirements and related capital-structure disclosures. Its public-company records also identify GRTX common stock on the OTCQB Market and provide formal disclosure of financial results, reporting obligations, risk-related matters and corporate actions affecting the company’s oncology development business.
Galera Therapeutics, Inc. amended its charter to change its capital structure and shareholder rights. The company increased authorized common stock from 200 million shares to 400 million shares through a Certificate of Amendment filed on May 11, 2026, after stockholder approval at the May 8, 2026 annual meeting.
A second charter amendment filed on May 12, 2026 gives stockholders a right to act by written consent. On the same day, the board adopted Amended and Restated Bylaws that implement the written consent right and related procedures, aligning the bylaws with the new charter provisions.
Galera Therapeutics reported a modest net loss of $1.6 million for the quarter ended March 31, 2026, down slightly from $1.6 million a year earlier, as operations have been scaled back. Research and development expense fell sharply to $15,000, while general and administrative costs were $1.6 million, reflecting a leaner business focused mainly on overhead and strategic work.
Cash and cash equivalents were $5.5 million and total assets $6.2 million, against an accumulated deficit of $308.9 million. Management concluded there is substantial doubt about the company’s ability to continue as a going concern beyond one year without new capital. To address this, Galera has agreed to merge with Obsidian Therapeutics and support a concurrent $350.0 million PIPE financing in Series C preferred stock, which, if completed, would leave Obsidian holders owning most of the combined company while Galera investors also receive contingent value rights tied to tilarginine and the Biossil asset sale.
Galera Therapeutics, Inc. reported the outcomes of its combined 2025 and 2026 annual meeting of stockholders held on May 8, 2026. Stockholders elected one Class III director and two Class I directors, ratified KPMG LLP as independent auditor for the year ending December 31, 2026, and approved the company’s executive compensation and an annual frequency for future Say-on-Pay votes.
Investors also approved several charter amendments. Authorized common shares will increase from 200 million to 400 million, giving the company more flexibility to issue stock. Stockholders granted the right to act by written consent and authorized the board to implement a reverse stock split at a ratio between 1-for-75 and 1-for-200 at a future time of the board’s choosing.
Galera Therapeutics, Inc. reported initial insider holdings for Emerald Bioventures, LLC and Timothy Opler as 10% owners. Emerald directly holds 40,216,160 shares of Common Stock and 20,813.818619 shares of Series B Non-Voting Convertible Preferred Stock. Each Series B share is convertible, at the board’s discretion, into 1,000 shares of Common Stock, totaling 20,813,818.6 underlying Common shares, and has no expiration date. Opler is Emerald’s managing member and may be deemed to beneficially own the securities held by Emerald.
Emerald Bioventures, LLC and Timothy Opler report beneficial ownership of 40,216,160 shares of Galera Therapeutics common stock, representing approximately 26.5% of the class. This stake reflects Nova Pharmaceuticals merger consideration, a December 2024 private placement, and a partial mandatory conversion of Series B preferred stock.
Emerald bought 3,057,973 Galera common shares for about $199,991 in the December 2024 private placement and received Series B Non-Voting Convertible Preferred Stock in the Nova merger. On April 7, 2026, 37,158.1873807108 Series B shares converted into 37,158,187 common shares, leaving 20,813.8186192892 Series B shares, which are not yet convertible without shareholder approval.
Emerald and other insiders entered stockholder support agreements covering about 51.1% of Galera’s outstanding capital stock to vote in favor of Galera’s planned merger with Obsidian Therapeutics and related transactions. The filing states the position is held for investment, while preserving flexibility to buy or sell Galera securities over time.
Galera Therapeutics, Inc. disclosed a proposed merger agreement dated April 14, 2026 under which Galera and Obsidian Therapeutics will combine into a newly-formed parent, with Galera and Obsidian each becoming wholly owned subsidiaries of the parent following the Galera Merger. The companies said the combined entity will file a registration statement on Form S-4 containing a proxy statement/prospectus and that materials will be mailed to Galera stockholders.
The filing also includes an Obsidian press release announcing an oral presentation of Phase 2 OBX-115 data in advanced melanoma at the 2026 ASCO Annual Meeting (May 29–June 2, 2026). The release describes OBX-115 as an engineered TIL therapy armored with membrane-bound IL15 and references ongoing Phase 1/2 Agni-01 (NCT06060613) clinical development.
Galera Therapeutics disclosed a pending merger with Obsidian Therapeutics under an Agreement and Plan of Merger dated April 14, 2026, pursuant to which Galera and Obsidian will each merge into newly formed subsidiaries of Gazelle Parent, Inc.
The companies say a registration statement on Form S-4 (including a proxy statement/prospectus) will be filed and mailed to Galera stockholders; additional SEC filings and a concurrent private placement financing are referenced.
Galera Therapeutics is holding a combined 2025–2026 virtual annual meeting on May 8, 2026 to elect directors, ratify its auditor, hold advisory say‑on‑pay votes, and approve several charter amendments.
Stockholders will vote on increasing authorized common stock from 200 million to 400 million shares, allowing action by written consent, and authorizing a reverse stock split at a ratio between 1:75 and 1:200. These changes are designed in part to support a planned all‑stock merger with Obsidian Therapeutics and a concurrent $350 million private placement that is expected to fund the combined company into the second half of 2028 and through key 2027 clinical milestones. As of April 10, 2026, Galera had 160,429,783 common shares outstanding and 39,373,206 shares reserved under options, RSUs and warrants.
Galera Therapeutics and Obsidian Therapeutics entered a definitive all‑stock merger agreement to form a newly formed company expected to operate as Obsidian Therapeutics, Inc., and to apply to list on Nasdaq under the ticker OBX. The companies have secured commitments for an oversubscribed private placement expected to raise $350 million that is planned to close immediately prior to the merger.
The combined company’s cash and cash equivalents at closing, including the private placement, is anticipated to provide runway into the second half of 2028, supporting Obsidian’s lead product OBX‑115 through key clinical readouts: Phase 1 NSCLC data expected in H1 2027 and melanoma topline data by year‑end 2027. Under the merger terms, pre‑closing Galera stockholders (excluding private placement participants) are expected to own ~1.8% of the combined company, pre‑closing Obsidian stockholders ~53.2%, and private placement investors ~45.0%. The transaction is subject to customary closing conditions and stockholder approvals and is expected to close by Q3 2026.